Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (41-50 of 123) with videos related to

Pageof 13
Sort By:
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Frontiers in Immunology|November 15, 2021
Mechanisms of Immune Checkpoint Inhibitor-Mediated ColitisHarm Westdorp, Mark W D Sweep, Mark A J Gorris, et al.
Clinical and Experimental Immunology|December 12, 2024
Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanomaStefan G van Ravensteijn, Avital L Amir, Daniele V F Tauriello, et al.
Annals of Surgical Oncology|January 4, 2026
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?Emilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Annals of Surgical Oncology|February 5, 2026
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer SurgeryEmilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Clinical Nuclear Medicine|May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief CommunicationBernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
European Urology|December 27, 2015
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell CarcinomaConstantijn H J Muselaers, Marye J Boers-Sonderen, Tim J van Oostenbrugge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2014
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinomaConstantijn H J Muselaers, Alexander B Stillebroer, Ingrid M E Desar, et al.
Oncoimmunology|January 18, 2021
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccinationWouter W van Willigen, Martine Bloemendal, Marye J Boers-Sonderen, et al.
Oncotarget|October 9, 2015
Better survival of renal cell carcinoma in patients with inflammatory bowel diseaseLauranne A A P Derikx, Loes H C Nissen, Joost P H Drenth, et al.
Pageof 13

Showing results (41-50 of 123) with videos related to

Sort By:
Pageof 13
Clinical Nuclear Medicine|May 27, 2025
Imaging Proliferation of Stage IV Cutaneous Melanoma With 18 F-FLT PET/CT : A Potential Noninvasive Tool for Predicting Treatment Resistance to Targeted Therapy?Bernies van der Hiel, Wouter V Vogel, Alfons J M van den Eertwegh, et al.
Frontiers in Immunology|November 15, 2021
Mechanisms of Immune Checkpoint Inhibitor-Mediated ColitisHarm Westdorp, Mark W D Sweep, Mark A J Gorris, et al.
Clinical and Experimental Immunology|December 12, 2024
Exploring the relation between TGF-β pathway activity and response to checkpoint inhibition in patients with metastatic melanomaStefan G van Ravensteijn, Avital L Amir, Daniele V F Tauriello, et al.
Annals of Surgical Oncology|January 4, 2026
The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate our Former Strategy?Emilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Annals of Surgical Oncology|February 5, 2026
ASO Visual Abstract: The Clinical Impact of the Surgical Removal of the Internal Mammary Chain Sentinel Node in Breast Cancer Patients: Do We Need to De-Escalate Our Former Strategy? Reevaluating the Role of Internal Mammary Sentinel Node Removal in Breast Cancer SurgeryEmilie M A L C Fentener van Vlissingen, Emily L Postma, Astrid N Scholten, et al.
Clinical Nuclear Medicine|May 20, 2024
Baseline and on Treatment Biodistribution Variability of 18 F-FLT Uptake in Patients With Advanced Melanoma: Brief CommunicationBernies van der Hiel, Else A Aalbersberg, Alfons J M van den Eertwegh, et al.
European Urology|December 27, 2015
Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell CarcinomaConstantijn H J Muselaers, Marye J Boers-Sonderen, Tim J van Oostenbrugge, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2014
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinomaConstantijn H J Muselaers, Alexander B Stillebroer, Ingrid M E Desar, et al.
Oncoimmunology|January 18, 2021
Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccinationWouter W van Willigen, Martine Bloemendal, Marye J Boers-Sonderen, et al.
Oncotarget|October 9, 2015
Better survival of renal cell carcinoma in patients with inflammatory bowel diseaseLauranne A A P Derikx, Loes H C Nissen, Joost P H Drenth, et al.
Pageof 13